国家银屑病基金会COVID-19工作组指南第2版:银屑病管理、疫苗与治疗更新
国家银屑病基金会COVID-19工作组更新了疫情期间银屑病管理指南。工作组由18名投票成员组成,采用Delphi流程,更新了原有22条声明并新增5条推荐,所有声明平均投票均属同意类别。指南涵盖疾病及治疗对COVID-19风险的影响、疫情期间医疗优化、疫苗接种及感染后处理。
要点
- 更新22条原有声明并新增5条推荐,指导疫情期间银屑病管理。
- 所有声明投票均达同意,13条高共识、14条中等共识。
- 指南涵盖疫苗、治疗调整及感染后处理等临床问题。
核心结论
- 工作组更新了22条声明并新增5条推荐,为银屑病患者在COVID-19疫情期间的管理提供指导。
研究设计与样本
- 工作组包括18名投票成员,专长于皮肤科、风湿科、流行病学、感染病和重症监护,并有非投票成员补充。
- 采用Delphi流程,临床问题来源于国家银屑病基金会收到的咨询。
主要发现
- 所有声明平均投票均属同意类别,其中13条高共识、14条中等共识。
关键数值与推荐
- 更新了22条原有声明的证据并新增5条推荐。
- 13条声明达高共识,14条达中等共识。
临床怎么用
- 指导银屑病疾病及其治疗对COVID-19风险的影响。
- 指导疫情期间医疗护理的优化。
- 指导患者降低SARS-CoV-2感染风险的措施(包括新型疫苗接种)。
- 指导患者感染COVID-19后的处理。
局限性
- 许多指导声明背后的证据质量或数量参差不齐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic. STUDY DESIGN: The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation staff. Clinical questions relevant to the psoriatic disease community were informed by inquiries received by the National Psoriasis Foundation. A Delphi process was conducted. RESULTS: The TF updated evidence for the original 22 statements and added 5 new recommendations. The average of the votes was within the category of agreement for all statements, 13 with high consensus and 14 with moderate consensus. LIMITATIONS: The evidence behind many guidance statements is variable in quality and/or quantity. CONCLUSIONS: These statements provide guidance for the treatment of patients with psoriatic disease on topics including how the disease and its treatments affect COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 (including novel vaccination), and what they should do if they develop COVID-19. The guidance is a living document that is continuously updated by the TF as data emerge.
引用
- Gelfand JM, Armstrong AW, Bell S, et al. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol. 2021. PMID: 33422626. doi:10.1016/j.jaad.2020.12.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。